Last checked at 
LONDON (Alliance News) - Cell-based therapeutics developer ReNeuron Group PLC on Thursday said it has selected glioblastoma multiforme as the first clinical target for its exosome nanomedicine platform.
Glioblastoma multiforme accounts for 16% of all diagnosed brain cancers, the company said.
The group is now pursuing pre-clinical development of its selected exosome nanomedicine candidate, ExoPr0, targeting glioblastoma multiforme.
"ReNeuron is a global leader in the exciting new field of exosome therapeutics and the selection of our ExoPr0 therapeutic candidate, initially targeting glioblastoma, expands our therapeutic pipeline into oncology, a field with huge therapeutic and commercial potential," said Olav Hellebo, ReNeuron's chief executive.
ReNeuron shares were up 1.5% to 3.42 pence Thursday.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
